Hamostaseologie
DOI: 10.1055/a-2238-4782
Nikica Sabljic
1
Clinic of Hematology, University Clinical Center of Serbia, Belgrade, Serbia
,
Mirjana Mitrovic
1
Clinic of Hematology, University Clinical Center of Serbia, Belgrade, Serbia
2
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
,
Nikola Pantic
1
Clinic of Hematology, University Clinical Center of Serbia, Belgrade, Serbia
,
Jecko Thachil
3
Department of Hematology, Manchester Royal Infirmary, Manchester, United Kingdom
› Author Affiliations
Funding The authors received no financial support for the research, authorship, and/or publication of this article.
› Further Information
Also available at
![SFX Search]()
Buy Article Permissions and Reprints
Abstract
Despite enormous improvement in the management of patients with acute promyelocytic leukemia (APL), the distinctive coagulopathy observed at presentation in affected patients is often life-threatening. While hemorrhagic manifestations are well known and described in this setting, APL-related thromboses are underappreciated. Data regarding this complication are scarce showing variable incidence. Furthermore, risk factors for thrombosis are inconsistent and unreliable; so, differentiation of increased risk of hemorrhage from an increased thrombotic risk is quite difficult in the absence of adequate predictive scores. Besides, prophylactic use of anticoagulants and recombinant thrombomodulin are a matter of ongoing debate. Also, due to the common feature of thrombocytopenia and other hemorrhagic risks, patients with APL are excluded from trials analyzing anticoagulant prophylaxis in cancers; so, data from prospective trials are lacking. A detailed analysis of thrombotic risks in APL with the development of a reliable risk stratification model is needed to further improve the care of APL patients.
Keywords
acute promyelocytic leukemia -
thrombosis -
hypercoagulability
Authors' Contribution
N.S. researched the literature, critically analyzed data, and drafted the manuscript. M.M. and J.T. brought the idea, analyzed literature, and revised and critically appraised the manuscript. N.P. designed table and figure and revised the manuscript.
Publication History
Received: 22 October 2023
Accepted: 03 January 2024
Article published online:
11 March 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
References
1
Tallman MS,
Altman JK.
How I treat acute promyelocytic leukemia. Blood 2009; 114 (25) 5126-5135
2
David S,
Mathews V.
Mechanisms and management of coagulopathy in acute promyelocytic leukemia. Thromb Res 2018; 164 (Suppl. 01) S82-S88
3
Li G,
Wu J,
Li R.
et al.
Improvement of early death in acute promyelocytic leukemia: a population-based analysis. Clin Lymphoma Myeloma Leuk 2023; 23 (02) e78-e84
4
Avvisati G,
Petti MC,
Lo-Coco F.
et al;
GIMEMA (Gruppo Italiano Malattie Ematologische dell'Adulto) Italian Cooperative Group.
Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood 2002; 100 (09) 3141-3146
5
Mitrovic M,
Suvajdzic N,
Bogdanovic A.
et al.
International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation ≥ 6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia. Med Oncol 2013; 30 (01) 478
6
Gill H,
Raghupathy R,
Lee CYY.
et al.
Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021. BMC Cancer 2023; 23 (01) 141
7
Breen KA,
Grimwade D,
Hunt BJ.
The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia. Br J Haematol 2012; 156 (01) 24-36
8
Dally N,
Hoffman R,
Haddad N,
Sarig G,
Rowe JM,
Brenner B.
Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients. Thromb Res 2005; 116 (02) 109-114
9
De Stefano V,
Sorà F,
Rossi E.
et al.
The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 2005; 3 (09) 1985-1992
10
Breccia M,
Avvisati G,
Latagliata R.
et al.
Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. Leukemia 2007; 21 (01) 79-83
11
Montesinos P,
Bergua JM,
Vellenga E.
et al.
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 2009; 113 (04) 775-783
12
Chang H,
Kuo MC,
Shih LY.
et al.
Acute promyelocytic leukemia-associated thrombosis. Acta Haematol 2013; 130 (01) 1-6
13
Mitrovic M,
Suvajdzic N,
Elezovic I.
et al.
Thrombotic events in acute promyelocytic leukemia. Thromb Res 2015; 135 (04) 588-593
14
Bai Y,
Shi M,
Yang X.
et al.
The value of FDP/FIB and D-dimer/FIB ratios in predicting high-risk APL-related thrombosis. Leuk Res 2019; 79: 34-37
15
Xiao M,
Zhou P,
Liu Y.
et al.
Predictive factors for differentiating thrombohemorrhagic disorders in high-risk acute promyelocytic leukemia. Thromb Res 2022; 210: 33-41
16
Zhang X,
Guo X.
Risk factors of thrombosis in Chinese subjects with acute promyelocytic leukemia. Thromb J 2021; 19 (01) 42
17
Ben Salah M,
Bchir M,
Berred R.
et al.
PB1802: Acute promyelocytic leukemia and thrombosis: How to identify the high-risk patients?. HemaSphere 2022; 6: 1682-1683
18
Martella F,
Cerrano M,
Di Cuonzo D.
et al.
Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study. Ann Hematol 2022; 101 (04) 855-867
19
Mitrovic M,
Virijevic M,
Pantic N.
et al.
P1692: Predictive model for vein thromboembolic events developed in patients with acute myeloid leukemia. HemaSphere 2022; 6: 1573-1574
20
Del Principe MI,
Del Principe D,
Venditti A.
Thrombosis in adult patients with acute leukemia. Curr Opin Oncol 2017; 29 (06) 448-454
21
Cortelezzi A,
Moia M,
Falanga A.
et al;
CATHEM Study Group.
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol 2005; 129 (06) 811-817
22
McKeown C,
Ricciuti A,
Agha M.
et al.
A prospective study of the use of central venous catheters in patients newly diagnosed with acute myeloid leukemia treated with induction chemotherapy. Support Care Cancer 2022; 30 (02) 1673-1679
23
Sanz MA,
Fenaux P,
Tallman MS.
et al.
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood 2019; 133 (15) 1630-1643
24
Escudier SM,
Kantarjian HM,
Estey EH.
Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. Leuk Lymphoma 1996; 20 (5-6): 435-439
25
Teng-Fei S,
Diyaer A,
Hong-Ming Z.
et al.
Evolving of treatment paradigms and challenges in acute promyelocytic leukaemia: a real-world analysis of 1105 patients over the last three decades. Transl Oncol 2022; 25: 101522
26
Khorana AA,
Francis CW,
Culakova E,
Kuderer NM,
Lyman GH.
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5 (03) 632-634
27
Khadka S,
Solanki D,
Singh J.
et al.
Trends and outcomes of venous thromboembolism in adult hospitalizations with acute myeloid leukemia: analysis of nationwide inpatient sample from 2010 to 2014. Postgrad Med 2021; 133 (02) 160-165
28
Gangaraju R,
Gahagan A,
Bhatia S,
Kenzik K.
Venous-thromboembolism in elderly patients with acute myeloid leukemia. Thromb Res 2021; 200: 9-11
29
Hellou T,
Cohen O,
Avigdor A.
et al.
The occurrence of thrombosis during intensive chemotherapy treatment for acute myeloid leukemia patients does not impact on long-term survival. Ann Hematol 2023; 102 (05) 1037-1043
30
Paterno G,
Palmieri R,
Forte V.
et al.
Predictors of early thrombotic events in adult patients with acute myeloid leukemia: a real-world experience. Cancers (Basel) 2022; 14 (22) 5640
31
Mitrovic M,
Pantic N,
Sabljic N.
et al.
Arterial thrombosis in patients with acute myeloid leukemia: incidence and risk factors. Cancers (Basel) 2023; 15 (11) 3060
32
Orsi FA,
Lijfering WM,
Geersing GJ.
et al.
Glucocorticoid use and risk of first and recurrent venous thromboembolism: self-controlled case-series and cohort study. Br J Haematol 2021; 193 (06) 1194-1202
33
Majoor CJ,
Sneeboer MM,
de Kievit A.
et al.
The influence of corticosteroids on hemostasis in healthy subjects. J Thromb Haemost 2016; 14 (04) 716-723
34
Mirza AS,
Yun S,
Ali NA.
et al.
Validation of the Khorana score in acute myeloid leukemia patients: a single-institution experience. Thromb J 2019; 17: 13
35
Al-Ani F,
Wang YP,
Lazo-Langner A.
Development of a clinical prediction rule for venous thromboembolism in patients with acute leukemia. Thromb Haemost 2020; 120 (02) 322-328
36
Sanz MA,
Montesinos P.
Advances in the management of coagulopathy in acute promyelocytic leukemia. Thromb Res 2020; 191 (Suppl. 01) S63-S67
37
Hambley BC,
Tomuleasa C,
Ghiaur G.
Coagulopathy in acute promyelocytic leukemia: Can we go beyond supportive care?. Front Med (Lausanne) 2021; 8: 722614
38
Zhao H,
Sun J,
Yan L.
et al.
Tissue factor-bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study. Ann Hematol 2021; 100 (06) 1473-1483
39
Speiser W,
Kapiotis S,
Kopp CW.
et al.
Effect of intradermal tumor necrosis factor-alpha-induced inflammation on coagulation factors in dermal vessel endothelium. An in vivo study of human skin biopsies. Thromb Haemost 2001; 85 (02) 362-367
40
Szotowski B,
Antoniak S,
Poller W,
Schultheiss HP,
Rauch U.
Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 2005; 96 (12) 1233-1239
41
Schleef RR,
Bevilacqua MP,
Sawdey M,
Gimbrone Jr MA,
Loskutoff DJ.
Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 1988; 263 (12) 5797-5803
42
Nan B,
Lin P,
Lumsden AB,
Yao Q,
Chen C.
Effects of TNF-alpha and curcumin on the expression of thrombomodulin and endothelial protein C receptor in human endothelial cells. Thromb Res 2005; 115 (05) 417-426
43
Barbui T,
Finazzi G,
Falanga A.
The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998; 91 (09) 3093-3102
44
Luo Q,
Wei G,
Wang X.
et al.
All-trans retinoic acid impairs platelet function and thrombus formation and inhibits protein kinase CßI/δ phosphorylation. Thromb Haemost 2019; 119 (10) 1655-1664
45
Choudhry A,
DeLoughery TG.
Bleeding and thrombosis in acute promyelocytic leukemia. Am J Hematol 2012; 87 (06) 596-603
46
Wartha F,
Henriques-Normark B.
ETosis: a novel cell death pathway. Sci Signal 2008; 1 (21) pe25
47
Li T,
Ma R,
Zhang Y.
et al.
Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy. Cell Death Dis 2018; 9 (02) 75
48
Swystun LL,
Mukherjee S,
Liaw PC.
Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus. J Thromb Haemost 2011; 9 (11) 2313-2321
49
Milic DJ,
Pejcic VD,
Zivic SS.
et al.
Coagulation status and the presence of postoperative deep vein thrombosis in patients undergoing laparoscopic cholecystectomy. Surg Endosc 2007; 21 (09) 1588-1592
50
Mao C,
Xiong Y,
Fan C.
Comparison between thromboelastography and conventional coagulation assays in patients with deep vein thrombosis. Clin Chim Acta 2021; 520: 208-213
51
Brill JB,
Badiee J,
Zander AL.
et al.
The rate of deep vein thrombosis doubles in trauma patients with hypercoagulable thromboelastography. J Trauma Acute Care Surg 2017; 83 (03) 413-419
52
Park MS,
Martini WZ,
Dubick MA.
et al.
Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. J Trauma 2009; 67 (02) 266-275 , discussion 275–276
53
Hvitfeldt Poulsen L,
Christiansen K,
Sørensen B,
Ingerslev J.
Whole blood thrombelastographic coagulation profiles using minimal tissue factor activation can display hypercoagulation in thrombosis-prone patients. Scand J Clin Lab Invest 2006; 66 (04) 329-336
54
Konstantinides SV,
Meyer G,
Becattini C.
et al;
ESC Scientific Document Group.
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
55
Ikezoe T.
Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin. Int J Hematol 2014; 100 (01) 27-37
56
Matsuda K,
Jo T,
Toyama K.
et al.
Efficacy of recombinant human soluble thrombomodulin in induction therapy for acute promyelocytic leukemia. Thromb Res 2021; 202: 173-175
留言 (0)